Ensysce Biosciences, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
ENSC$0.36-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(1,945,573) | $(3,116,563) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Accrued interest | 2,947 | 27,283 | ||
| Amortization of original issue discount and debt issuance costs | - | 1,171,465 | ||
| Change in fair value of liability classified warrants | (9,916) | (8,955) | ||
| Consultant compensation | 46,093 | - | ||
| Stock-based compensation | 16,251 | 33,207 | ||
| Changes in operating assets and liabilities: | ||||
| Unbilled receivable | 102,113 | 1,337 | ||
| Prepaid expenses and other assets | 433,659 | (86,697) | ||
| Accounts payable | (741,784) | (1,295,655) | ||
| Accrued expenses and other liabilities | 388,798 | (133,825) | ||
| Net cash used in operating activities | (1,707,412) | (3,408,403) | ||
| Cash flows from financing activities: | ||||
| Proceeds from public offerings | 1,100,006 | - | ||
| Proceeds from warrant exercises | 347,995 | 2,075,219 | ||
| Proceeds from warrant inducement, net of issuance costs | - | 4,718,295 | ||
| Transaction costs from public offerings | (142,950) | - | ||
| Transaction costs associated with warrant inducements | - | (465,494) | ||
| Repayment of convertible notes | - | (485,190) | ||
| Repayment of financed insurance premiums | (47,225) | (153,682) | ||
| Net cash provided by financing activities | 1,257,826 | 5,689,148 | ||
| Increase (decrease) in cash and cash equivalents | (449,586) | 2,280,745 | ||
| Cash and cash equivalents beginning of period | 3,502,077 | 1,123,604 | ||
| Cash and cash equivalents end of period | $3,052,491 | $3,404,349 | ||
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Incremental fair value of February 2024 Warrant Inducement | $ | - | $5,167,372 | |
| Conversion of convertible notes into common stock | $ | - | $1,168,600 | |
| Transaction costs from warrant inducement | $ | - | $341,368 | |
| Transaction costs from public offerings | $61,243 | $ | - | |
| Deemed dividend related to warrants down round provision | $ | - | $290 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.